Rigel Pharmaceuticals
RIGL
121 hedge funds and large institutions have $248M invested in Rigel Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 49 increasing their positions, 31 reducing their positions, and 10 closing their positions.
229% more call options, than puts
Call options by funds: $115K | Put options by funds: $35K
58% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 31
26% more capital invested
Capital invested by funds: $197M → $248M (+$50.9M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 122 → 121 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
Top Sellers
| 1 |
BC
Broadfin Capital
New York
|
-$6.06M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$843K |
| 3 |
UBS AM
Chicago,
Illinois
|
-$634K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$619K |
| 5 |
MOACM
Mutual of America Capital Management
New York
|
-$422K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
126
Tower Research Capital (TRC)
New York
| – | -$29K | -1,179 | Closed |
|
127
UBS Group
Zurich,
Switzerland
| – | -$8K | -343 | Closed |
|
128
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$5K | -190 | Closed |
|
129
Simplex Trading
Chicago,
Illinois
| – | -$697 | -23 | Closed |
|
RIGL Hedge Fund Activity: Q4 2015 in Review
121 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2015, worth a combined $248M — up 26% from $197M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RIGL and 9 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 49 added.
The largest buyer was Rock Springs Capital Management, opening a new position worth an estimated $3.34M. The largest seller was Broadfin Capital, cutting an estimated $6.06M.
- 121 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2015, down from 122 in Q3 2015.
- Funds reported $248M of Rigel Pharmaceuticals stock for Q4 2015, up 26% quarter-over-quarter.
- 9 funds opened new Rigel Pharmaceuticals positions in Q4 2015 and 10 closed out, a net change of -1 holder.
- The largest Rigel Pharmaceuticals buyer in Q4 2015 was Rock Springs Capital Management, an estimated $3.34M added.
- The largest Rigel Pharmaceuticals seller in Q4 2015 was Broadfin Capital, an estimated $6.06M sold.
Based on aggregated 13F filings for Q4 2015.